NO319895B1 - Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. - Google Patents
Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. Download PDFInfo
- Publication number
- NO319895B1 NO319895B1 NO19972725A NO972725A NO319895B1 NO 319895 B1 NO319895 B1 NO 319895B1 NO 19972725 A NO19972725 A NO 19972725A NO 972725 A NO972725 A NO 972725A NO 319895 B1 NO319895 B1 NO 319895B1
- Authority
- NO
- Norway
- Prior art keywords
- rhepo
- spray
- dried
- drying
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 34
- 239000000203 mixture Substances 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 238000001035 drying Methods 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000000889 atomisation Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- 102000003951 Erythropoietin Human genes 0.000 description 8
- 108090000394 Erythropoietin Proteins 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012527 feed solution Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 238000012430 stability testing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35794794A | 1994-12-16 | 1994-12-16 | |
| PCT/US1995/016416 WO1996018647A1 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO972725D0 NO972725D0 (no) | 1997-06-13 |
| NO972725L NO972725L (no) | 1997-08-06 |
| NO319895B1 true NO319895B1 (no) | 2005-09-26 |
Family
ID=23407689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19972725A NO319895B1 (no) | 1994-12-16 | 1997-06-13 | Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6001800A (de) |
| EP (1) | EP0805822B2 (de) |
| JP (1) | JP4039686B2 (de) |
| CN (1) | CN1117762C (de) |
| AT (1) | ATE265468T1 (de) |
| AU (1) | AU697287B2 (de) |
| CA (1) | CA2207615C (de) |
| DE (1) | DE69532970T3 (de) |
| DK (1) | DK0805822T4 (de) |
| ES (1) | ES2219672T5 (de) |
| FI (1) | FI119723B (de) |
| HU (1) | HU222370B1 (de) |
| IL (1) | IL116085A (de) |
| NO (1) | NO319895B1 (de) |
| NZ (1) | NZ298981A (de) |
| PT (1) | PT805822E (de) |
| TW (1) | TW425287B (de) |
| WO (1) | WO1996018647A1 (de) |
| ZA (1) | ZA9510708B (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19539574A1 (de) * | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
| US6151332A (en) | 1997-06-20 | 2000-11-21 | Tantivy Communications, Inc. | Protocol conversion and bandwidth reduction technique providing multiple nB+D ISDN basic rate interface links over a wireless code division multiple access communication system |
| US6542481B2 (en) | 1998-06-01 | 2003-04-01 | Tantivy Communications, Inc. | Dynamic bandwidth allocation for multiple access communication using session queues |
| US6081536A (en) * | 1997-06-20 | 2000-06-27 | Tantivy Communications, Inc. | Dynamic bandwidth allocation to transmit a wireless protocol across a code division multiple access (CDMA) radio link |
| EP0913177A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
| US6222832B1 (en) | 1998-06-01 | 2001-04-24 | Tantivy Communications, Inc. | Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system |
| US7936728B2 (en) | 1997-12-17 | 2011-05-03 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
| US8175120B2 (en) | 2000-02-07 | 2012-05-08 | Ipr Licensing, Inc. | Minimal maintenance link to support synchronization |
| US9525923B2 (en) | 1997-12-17 | 2016-12-20 | Intel Corporation | Multi-detection of heartbeat to reduce error probability |
| US7496072B2 (en) | 1997-12-17 | 2009-02-24 | Interdigital Technology Corporation | System and method for controlling signal strength over a reverse link of a CDMA wireless communication system |
| US7394791B2 (en) | 1997-12-17 | 2008-07-01 | Interdigital Technology Corporation | Multi-detection of heartbeat to reduce error probability |
| US7773566B2 (en) | 1998-06-01 | 2010-08-10 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
| US8134980B2 (en) | 1998-06-01 | 2012-03-13 | Ipr Licensing, Inc. | Transmittal of heartbeat signal at a lower level than heartbeat request |
| US6526034B1 (en) | 1999-09-21 | 2003-02-25 | Tantivy Communications, Inc. | Dual mode subscriber unit for short range, high rate and long range, lower rate data communications |
| US8155096B1 (en) | 2000-12-01 | 2012-04-10 | Ipr Licensing Inc. | Antenna control system and method |
| US7551663B1 (en) | 2001-02-01 | 2009-06-23 | Ipr Licensing, Inc. | Use of correlation combination to achieve channel detection |
| US6954448B2 (en) | 2001-02-01 | 2005-10-11 | Ipr Licensing, Inc. | Alternate channel for carrying selected message types |
| PT1471871E (pt) | 2001-02-02 | 2007-06-05 | Ortho Mcneil Pharm Inc | Tratamento de disfunção neurológica compreendendo sulfamatos de frutopiranose e eritropoietina |
| KR100665077B1 (ko) | 2001-06-13 | 2007-01-09 | 탄티비 커뮤니케이션즈 인코포레이티드 | 하트비트 요구보다 낮은 레벨로의 하트비트 신호의 전송 |
| WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| AU2003291527A1 (en) * | 2002-12-31 | 2004-07-29 | Nektar Therapeutics | Antibody-containing particles and compositions |
| EP1683812B1 (de) | 2003-11-14 | 2014-11-12 | Chugai Seiyaku Kabushiki Kaisha | Mikroteilchen aus vernetztem polysaccharid und deren herstellungsverfahren |
| SG158186A1 (en) | 2004-12-22 | 2010-01-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| ATE542920T1 (de) | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
| CN101454461A (zh) | 2005-11-16 | 2009-06-10 | Ambrx公司 | 包括非天然氨基酸的方法和组合物 |
| EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
| JP2010510794A (ja) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| RU2537139C2 (ru) * | 2008-01-15 | 2014-12-27 | Эбботт Гмбх Унд Ко.Кг | Порошковые белковые композиции и способы их получения |
| NZ600382A (en) | 2008-07-23 | 2013-11-29 | Ambrx Inc | Modified bovine G-CSF polypeptides and their uses |
| PT104350A (pt) | 2009-01-23 | 2010-07-23 | Hovione Farmaci Ncia S A | Processo de isolamento de tigeciclina |
| EP2805965A1 (de) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen |
| CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| DK2661254T3 (da) | 2011-01-05 | 2017-11-06 | Hospira Inc | Sprøjtetørring af vancomycin |
| US9566241B2 (en) | 2012-02-21 | 2017-02-14 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| CN104984323B (zh) * | 2015-06-12 | 2018-05-01 | 北京四环生物制药有限公司 | 注射用重组人促红素冻干粉针剂 |
| CN105311624A (zh) * | 2015-11-23 | 2016-02-10 | 哈药集团生物工程有限公司 | 一种含有重组人促红素的药物组合物 |
| PL3849614T3 (pl) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Koniugaty polipeptydu interleukiny-2 i ich zastosowania |
| CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| EP4199968A1 (de) | 2020-08-20 | 2023-06-28 | Ambrx, Inc. | Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon |
| MX2023011480A (es) | 2021-04-03 | 2023-12-06 | Ambrx Inc | Conjugados anticuerpo anti-her2-fármaco y usos de estos. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57149228A (en) * | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
-
1995
- 1995-11-21 IL IL11608595A patent/IL116085A/xx not_active IP Right Cessation
- 1995-12-15 EP EP95943452A patent/EP0805822B2/de not_active Expired - Lifetime
- 1995-12-15 ES ES95943452T patent/ES2219672T5/es not_active Expired - Lifetime
- 1995-12-15 JP JP51929496A patent/JP4039686B2/ja not_active Expired - Lifetime
- 1995-12-15 WO PCT/US1995/016416 patent/WO1996018647A1/en not_active Ceased
- 1995-12-15 HU HU9800996A patent/HU222370B1/hu active IP Right Grant
- 1995-12-15 DK DK95943452.3T patent/DK0805822T4/da active
- 1995-12-15 ZA ZA9510708A patent/ZA9510708B/xx unknown
- 1995-12-15 PT PT95943452T patent/PT805822E/pt unknown
- 1995-12-15 DE DE69532970T patent/DE69532970T3/de not_active Expired - Lifetime
- 1995-12-15 AU AU44713/96A patent/AU697287B2/en not_active Expired
- 1995-12-15 NZ NZ298981A patent/NZ298981A/xx not_active IP Right Cessation
- 1995-12-15 CN CN95197638.9A patent/CN1117762C/zh not_active Expired - Lifetime
- 1995-12-15 AT AT95943452T patent/ATE265468T1/de active
- 1995-12-15 CA CA2207615A patent/CA2207615C/en not_active Expired - Lifetime
-
1996
- 1996-06-06 TW TW085106816A patent/TW425287B/zh not_active IP Right Cessation
- 1996-12-15 US US08/894,023 patent/US6001800A/en not_active Expired - Lifetime
-
1997
- 1997-06-13 NO NO19972725A patent/NO319895B1/no not_active IP Right Cessation
- 1997-06-16 FI FI972557A patent/FI119723B/fi not_active IP Right Cessation
-
1999
- 1999-10-12 US US09/415,726 patent/US6235710B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO319895B1 (no) | Fremgangsmate for fremstilling av spraytorket rhEPO, samt torr rhEPO fremsatt i henhold til denne metoden og sammensetning derav. | |
| Mumenthaler et al. | Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator | |
| Lee | Spray-drying of proteins | |
| CA2336376C (en) | Microparticle formulation for inhalation | |
| EP1932519B1 (de) | Formulierungen zur Proteinstabilisierung | |
| US6451349B1 (en) | Spray-drying process for the preparation of microparticles | |
| JPH08507064A (ja) | 有機溶媒を用いて処理したポリペプチドの賦形剤安定化 | |
| KR100705997B1 (ko) | 안정화된 hgf 동결건조제제 및 그 제조방법 | |
| NO316661B1 (no) | Fremgangsmate for forstovning av en insulindose og et insulinprodukt | |
| US9511116B2 (en) | Stable MIA/CD-RAP formulation | |
| CA2234724A1 (en) | Stable pharmaceutical forms of administration containing parathyroid hormone | |
| TWI285112B (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
| AU705094B2 (en) | Dry compositions | |
| JPH05331071A (ja) | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 | |
| JPH04208228A (ja) | インシュリン様成長因子ｉの乾燥製剤 | |
| MXPA97004504A (en) | Aspected eritropoyetin | |
| JP2001151694A (ja) | タンパク質粉体の製造法 | |
| MXPA01000105A (en) | Microparticle formulation for inhalation | |
| MXPA00012652A (en) | Improved process for preparing schiff base adducts of amines with o |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |